FDMT

Business Context and Reporting Period

Company: 4D Molecular Therapeutics, Inc. (FDMT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: 4DMT is a late-stage biotechnology company developing durable genetic medicines using its proprietary Therapeutic Vector Evolution (TVE) platform. The company focuses on retinal diseases (wet AMD, DME) and pulmonology (Cystic Fibrosis). It has no approved products and has not generated product revenue to date.

Key Financial Metrics

Note: Revenue in 2025 was driven primarily by a $85.0 million upfront payment from a new collaboration agreement.

Material Changes vs. Prior Period

• Revenue Surge: Revenue increased by $85.2 million (from $37,000 in 2024) due to the October 2025 Collaboration and License Agreement with Otsuka Pharmaceutical Co., Ltd., which included an $85.0 million upfront cash payment.
• Reduced Net Loss: Net loss decreased by $20.8 million (13%) to $140.1 million, primarily offset by the new collaboration revenue, despite higher operating expenses.
• Increased R&D Spend: R&D expenses rose 38% to $195.7 million, driven by a $35.5 million increase in clinical trial and consumable costs for the lead candidate 4D-150 and a $10.0 million increase in payroll (including one-time severance costs).
• Restructuring: In July 2025, the company reduced its workforce by approximately 25%, recording $3.2 million in severance and termination costs to prioritize the 4D-150 and 4D-710 programs.
• Capital Raises: The company raised approximately $93.3 million in net proceeds from an underwritten offering in November 2025 and $9.6 million via an at-the-market offering program.

Guidance, Outlook, and Management Commentary

Clinical Pipeline Progress:

• 4D-150 (Retina): The company completed enrollment for the 4FRONT-1 Phase 3 trial in wet AMD ahead of schedule (over 500 patients) in February 2026. Topline data is expected in the first half of 2027. The 4FRONT-2 global Phase 3 trial initiated in June 2025, with data expected in the second half of 2027. Positive interim data from the PRISM Phase 1/2 trial showed durable visual acuity maintenance and significant reduction in treatment burden.
• 4D-710 (Cystic Fibrosis): Phase 2 enrollment is underway following positive Phase 1 interim data demonstrating durable CFTR transgene expression. The company secured additional funding from the Cystic Fibrosis Foundation (CFF) totaling up to $11 million to support Phase 2 and Phase 3 readiness.

Strategic Partnerships:

• Otsuka Pharmaceutical: Granted exclusive rights to develop and commercialize 4D-150 in Japan, China, Australia, and other APAC markets. 4DMT retains rights in the U.S., Europe, and Latin America. Potential milestone payments total up to $335.5 million plus tiered double-digit royalties.
• Cystic Fibrosis Foundation: Continued funding support and a Joint Steering Committee established to guide 4D-710 development.

Liquidity and Outlook: Management believes existing cash and marketable securities ($514.0 million) are sufficient to fund operations for at least one year from the filing date. The company expects to continue incurring significant losses until product candidates are approved and commercialized. Future funding may be required through equity offerings, debt, or collaborations.

Risks: Key risks include the uncertainty of clinical trial outcomes, the need for substantial additional capital, regulatory approval delays, and the complexity of manufacturing AAV genetic medicines.

Key Facts for Investor Verification

• Phase 3 Enrollment Status: Verify the final enrollment numbers and patient demographics for the 4FRONT-1 and 4FRONT-2 trials to assess the robustness of the upcoming 2027 data readouts.
• Cash Burn Rate: Monitor quarterly cash usage to confirm the "at least one year" runway estimate remains valid given the high cost of Phase 3 trials.
• Otsuka Agreement Terms: Review the specific cost-sharing mechanisms and milestone definitions in the Otsuka agreement to understand future revenue recognition triggers.
• Manufacturing Capacity: Assess the company's internal cGMP capabilities and reliance on CDMOs for scaling production to meet Phase 3 and potential commercial demand.
• Regulatory Feedback: Track FDA and EMA feedback regarding the single Phase 3 trial design for 4D-150 in DME, as this impacts the path to approval.